GO
Loading...

GlaxoSmithKline PLC

More

  • GENEVA/ LONDON, March 5- Final stage of testing of an experimental Ebola vaccine being developed by Merck and NewLink Genetics will begin in Guinea on March 7, the World Health Organization said on Thursday. All three worst-hit countries- Guinea, Liberia and Sierra Leone- aim to conduct Phase III final-stage clinical trials of experimental vaccines.

  • LONDON, March 4- The idea of using vaccines to fight cancer has received a shot in the arm from a $1 billion deal between Bristol-Myers Squibb and Bavarian Nordic. Unfortunately, they have run into problems in practice, leading to a series of failures with experimental products such as Merck KGaA's Stimuvax and GlaxoSmithKline's MAGE-A3. The idea of combining...

  • Early movers: BRK.B, AAPL, LL, CAH, BSX & more Monday, 2 Mar 2015 | 7:50 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • LONDON, March 2- GlaxoSmithKline and Novartis said on Monday they had completed a series of asset swaps worth more than $20 billion that will reshape both drugmakers. GSK is forming a consumer health joint venture with Novartis, while at the same time buying the Swiss company's vaccines business and divesting its cancer drugs portfolio to Novartis.

  • DUBLIN, Feb 26- Malin, an Irish company set up by a number of former Elan executives to invest in privately held life science assets, said it plans to raise between 275 million and 325 million euros in one of Europe's biggest biotechnology IPOs. Former Elan chief executive Kelly Martin and chairman Bob Ingram, who sold the Irish stock market stalwart to Perrigo for...

  • The Biomedical Advanced Research and Development Authority has told the company that its anti-Ebola treatments should be efficient as Mapp Biopharmaceutical's ZMapp. The number of new cases has plummeted but officials have said much work still needs to be done before the virus is snuffed out in Liberia, Guinea and Sierra Leone, the three worst affected...

  • WASHINGTON, Feb 23- Novartis AG has won U.S. antitrust approval to buy GlaxoSmithKline's oncology drugs, with conditions, the U.S. Federal Trade Commission said on Monday. The deal is one of three related transactions announced in April 2014 in which GlaxoSmithKline would buy Novartis' global vaccine business, except for flu vaccines, Novartis would buy Glaxo's...

  • UPDATE 1-Novavax starts Ebola vaccine trial in humans Thursday, 12 Feb 2015 | 12:06 PM ET

    Feb 12- Novavax Inc has begun early-stage human trials of an Ebola vaccine that it hopes can win the race to become the most effective shot for the deadly virus. The company has the means to manufacture millions of doses of the vaccine every month and is seeking funding to develop it further, Chief Executive Stanley Erck told Reuters. Even as President Barack Obama...

  • Novavax starts Ebola vaccine trial in humans Thursday, 12 Feb 2015 | 8:27 AM ET

    Feb 12- Novavax Inc has begun early-stage testing of its Ebola vaccine in humans, the company said, less than five months after entering the race to develop a shot for the deadly virus. Other potential vaccines include those being developed by a NewLink Genetics Corp and Merck& Co Inc collaboration and by Johnson& Johnson and Bavarian Nordic A/S.

  • US firms in China: We feel less welcome here Tuesday, 10 Feb 2015 | 8:00 PM ET

    American businesses feel increasingly less welcome in China, according to a new survey, with rising protectionism in the mainland a top concern.

  • Feb 10- The Canadian government will require pharmaceutical companies to post public notices when drugs are not available or face fines, Health Minister Rona Ambrose said on Tuesday. The website, www.drugshortages.ca, lists more than 200 recent shortages of drugs made by companies including Valeant Pharmaceuticals Inc, GlaxoSmithKline PLC and Pfizer...

  • WASHINGTON, Feb 10- For the first time in 20 years, patients suffering from the eye disease glaucoma may soon have new treatments as several young companies look to shake up the $5.6 billion global market. No new class of medicine has been introduced since Pfizer Inc's N> Xalatan, known generically as latanoprost, in 1996.. The newcomers aim to disrupt...

  • Early movers: TWTR, MSG, EBAY, GPRO & more Friday, 6 Feb 2015 | 8:00 AM ET

    Some of the names on the move ahead of the open.

  • Lightning Round: Why you should buy Box again Thursday, 5 Feb 2015 | 7:48 PM ET
    Mad Money Lightning Round

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Wednesday's midday movers: Comcast, Apple & more Wednesday, 4 Feb 2015 | 12:16 PM ET
    Traders on the floor of the New York Stock Exchange.

    Take a look at some of Wednesday's midday movers:

  • Europe shares close mixed; LVMH, Greek banks soar Wednesday, 4 Feb 2015 | 11:40 AM ET

    European shares closed mixed on Wednesday, as investors reacted to earnings and hopes that the Greek debt dispute will be resolved.

  • GSK sales falls; firm upbeat on respiratory unit Wednesday, 4 Feb 2015 | 8:45 AM ET

    Shares of GlaxoSmithKline jumped on Wednesday, despite the company posting a 3 percent fall in full-year revenue.

  • *Novartis deal on track to close in first half 2015. GSK is also banking on an asset swap with Novartis to help revive its fortunes, and looking to unlock value by floating its HIV unit ViiV Healthcare. GSK is buying vaccines, selling cancer drugs and forming a consumer health joint venture with Novartis in a $20- billion transaction designed to ensure more stable...

  • LONDON, Feb 4- GlaxoSmithKline said on Wednesday it expected to start to regain market share in respiratory medicine after weak demand for lung drug Advair again hurt fourth-quarter sales, capping a rough year for Britain's top drugmaker. GSK is also banking on an asset swap with Novartis to help revive its fortunes, and looking to unlock value by floating its...

  • Stocks close up sharply, boosted by Greece and oil Monday, 2 Feb 2015 | 4:00 PM ET
    Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed sharply higher on encouraging news from the Eurozone and stronger oil prices.